CXCL12 and inherited lipid metabolism disorder: In addition, as mentioned elsewhere, increased serum CXCL12 levels are found in patients with dyslipidaemia, and statins used for the treatment of dyslipidaemia have been shown to reduce CXCL12 levels (probably through ACKR3), implicating the CXCL12/ACKR3 axis as a potential therapeutic target.